Morphine sulfate (MS) stimulates mesangial cell (MC) proliferation, a process central to development of glomerular disease. The purpose of this study was to examine if specific opioid receptors (OR) and signal transducer and activators of transcription 3 (STAT3) signaling are associated with MS-induced MC proliferation. C57Bl/6J and OR-specific knockout (KO) mice were treated for up to 6 weeks with PBS, MS (0.7-2.14 mg/Kg), naloxone (equimolar to MS), or MS+naloxone (n=6 per group). Glomerular volume and expression of PCNA, Thy1 and ED1/CD68 were analyzed in kidney sections in vivo.
INTRODUCTION
Opioids are a mainstay of treatment for pain associated with a variety of acute and chronic disease processes. While the untoward renal effects of non-opioid analgesics are well-known (11, 19) , the adverse effects of chronic opioid exposure are largely unknown, with the exception of the inadequately defined entity of heroin nephropathy, which many experts believe to be due to a contaminant and not heroin itself (1, 14, 16, 29, 41, 42) . Recent studies from our laboratory and others have shown that chronic treatment with MS leads to kidney pathology, proteinuria, elevated urinary creatinine, increased cell proliferation and glomerular volume expansion in tumorbearing C3H mice and rats (4, 7) .
Morphine sulfate (MS) is one of the most commonly used opioids and is a metabolite of heroin. There are three classical opioid receptors (OR) defined by their unique pharmacologic responses to various opioid ligands: delta (DOR), kappa (KOR), and mu (MOR) and the less well-characterized nociceptin/orphanin FQ. MS is capable of interacting with all three of the classical ORs (55). ORs, once thought to be located only in the central nervous system where they function in anti-nociception, have also been identified in the kidney (36, 40) . ORs appear to be functionally important in the kidney based on evidence suggesting that MS stimulates mesangial cell proliferation, migration and matrix synthesis in vitro in conditions analogous to chronic use in vivo (45, 46) and promotes renal medullary interstitial cell and fibroblast proliferation (47) (48) (49) . However, the cell-specific OR of importance and downstream signaling events remain unknown.
As mesangial cell proliferation is a hallmark of glomerular disease, we sought in this Page 3 of 45 4 study to identify the specific OR associated with MS-induced mesangial cell proliferation and the signaling pathway associated with it.
Amongst the signaling pathways, signal transducer and activator of transcription-3 (STAT3), a transcription factor, has been shown to mediate mesangial cell proliferation, epithelial tubule formation and glomerulosclerosis (9, 52, 59) . MS and MOR agonist DAMGO stimulate STAT3 phosphorylation in differentiated SH-SY5Y neuroblastoma cells and in endothelial cells (12, 56) , suggesting that MS may be acting via STAT3 pathway in stimulating MC proliferation.
Therefore, we examined the effect of chronic MS treatment on mesangial cells in vivo and the specific OR and signaling pathway associated with it. To ascertain the contribution of individual ORs, we utilized an in vivo model of chronic opioid therapy in OR-specific knockout mice and in wild-type mice treated with specific OR agonists and antagonists. We show that MS stimulates mesangial cell proliferation via KOR and a STAT3-dependent mechanism. 
METHODS

Reagents
Animal Models
All animal experiments complied with Institutional Animal Care and Use Committee (IACUC) approved protocols. C57BL/6J and KOR, DOR, and MOR knock-out mice produced on a C57Bl/6J background were used. Equal numbers of male and female mice were used. MOR-1 KO mice were generated by deleting exon 1 of the MOR-1 gene by using a targeted vector, in which exon 1 was replaced by a neomycin resistance cassette, as previously described (43) . DOR-KO mice were produced by the deletion of exon 2 of the murine DOR-1, which was replaced by a neomycin resistance cassette (60) . KOR-KO mice were produced by replacing exon 3 of the murine KOR-1 gene with the neomycin resistance cassette (26 RT-PCR Total RNA was isolated from the kidneys using Trizol reagent. Five µg of total RNA was reverse transcribed using the first strand synthesis system (Invitrogen, Carlsbad, CA).
PCRs were performed by using Taq and 5'-CCT TGG AAC CGG ACA GCA GAC G-3' (anti-sense nucleotides 757-778).
Amplification was performed for 30 cycles at 94°C for 50s, 56°C for 50s and 72°C for 50s with a final extension cycle for 10 min at 72°C in PTC-100 thermocycler (MJ Research, Waltham, MA). DNA samples were visualized by 2% agarose gel Negative controls were stained using mouse or rabbit IgG instead of 1° antibodies. during DNA synthesis) was added to the medium for the final 8 hours of treatment. Cells were incubated for 30 min with diluted peroxidase conjugated anti-BrdU antibody.
Absorbance was assessed at 370 nm with 492 nm as the reference wavelength utilizing a microplate ELISA reader. Appropriate control wells were used in each experiment.
Glomerular Filtration Rate (GFR)
We used the inulin clearance method to estimate GFR (13) . Mice were anesthetized with a combination of Inactin (thiobutabarbital sodium, 100 mg/kg, intraperitoneally) and ketamine (10 mg/kg). Additional doses of ketamine (5 mg/kg, intramuscularly) were administrated as required. The anesthetized mice were placed on a servo-controlled surgical table that maintained body temperature at 37°C, and a tracheostomy was 
Data and Statistical Analysis
Data are expressed as mean ± SD, except in mesangial cell proliferation studies data expressed as mean ± SE. Data were compared using ANOVA with Tukey Pairwise post-test comparisons between groups. Statistical significance was defined as p<0.05.
RESULTS
Classical ORs are Present on Mesangial Cells
OR activity has been suggested in the kidney based on the identification of opioid binding sites and opioid activity in the kidney (4, 36, 40) . However, the physical expression of ORs in the kidney remains unknown. Therefore, we first examined for the expression of MOR, DOR and KOR in the kidneys of WT, MOR-KO, DOR-KO and KOR-KO mice and in the mesangial cells. RT-PCR analysis of whole kidney and mesangial cell RNA revealed the expression of KOR and MOR ( Figure 1A ), but the expression of DOR was barely detectable in both kidney and mesangial cells. We next examined the expression of ORs in the kidney of OR-KO mice using an additional primer set for MOR and DOR each. MOR and KOR were expressed but DOR was not expressed in WT mouse kidney ( Fig 1B) . MOR-KO mice only expressed KOR, KOR-KO mice only expressed MOR, and neither expressed DOR, further supporting our initial observations ( Fig 1A) that DOR is not expressed in the mouse kidney. Based on our
RT-PCR findings and other studies that have identified tissue and cell-specific ORs (17,51,58), we next examined the effect of MS treatment on mouse kidney in vivo. Furthermore, morphine-induced increase in glomerular volume was time-dependent (Table 2 and Fig 2A) . Treatment of mice with morphine for 2 days did not show an increase in glomerular volume (PBS vs morphine, p>0.05), suggesting that acute treatment does not influence glomerular pathology. However, on d10 there was a 10% increase in glomerular volume, but was statistically not significant (PBS vs morphine, p=0.06). Glomerular volume continued to increase with time from 10 d to 3 wks and upto 6 wks, last period of observation (p<0.05 for MS treatment, 10d vs 3wks and 3 wks vs 6 wks). Six weeks of treatment also showed tubular hypertrophy, suggesting that glomerular changes precede tubular pathology with morphine treatment (Fig 2A, bottom right panel).
Morphine stimulates mesangial expansion and cell proliferation in mouse kidney MS stimulates mesangial cell proliferation in vitro. Increased mesangium can lead to glomerular volume expansion. Therefore, we examined if MS treatment leads to an increase in mesangium in mouse kidneys in vivo using Thy1 staining as a marker for
MCs. Immunofluorescent staining for Thy1 showed increased red fluorescence for
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Thy1 around the blue nuclei in the glomeruli of MS treated as compared to PBS treated mice, suggestive of increased MCs in a mesangial staining pattern (Fig. 3A-D) .
Enlarged glomeruli were evident at both low and high magnification in MS as compared to relatively smaller glomeruli in PBS treated animals. Western immunoblotting showed a 30% increase in band density for Thy1 in MS treated as compared to PBS treated mouse kidney lysates (Fig. 3D) . It therefore appears that MS stimulates MC proliferation in vivo in the glomerulus. Staining for PCNA, an antigen that is associated with DNA synthesis during cell proliferation, revealed an appreciable amount of red staining co-localized with the nuclear stain DAPI after 3 weeks of morphine treatment, that increased further after 6 weeks of treatment, whereas no staining was observed after PBS treatment (Fig. 4A-F 
Effect of Morphine Treatment on Kidney Function
We speculated that structural changes in the glomerulus would be accompanied by alteration in renal function. Indeed, we recently showed that MS-induced glomerulopathy was accompanied by increased blood flow in the kidney and decreased mean arterial pressure in tumor-bearing C3H mice (4). Therefore, we measured the GFR as measured by inulin clearance in wild-type mice after 3 weeks of treatment with MS. In this study, we did not observe a significant difference in GFR after MS treatment in C57/BL6 mice (3032 ±403 vs 3392 ± 1666 µl/min for PBS; p>0.05) (Fig. 5) . This lack of a change in renal function in MS-treated mice could be due to the strain of mouse and/or the techniques used. In the present study, mice were anesthetized for a significant period of time, and anesthetics may influence renal hemodynamics via the sympathetic nervous system (37) . Therefore, it is likely that the effect of MS was masked due to the anesthesia used in this study. In some rat models, however, an increased cell turnover rate and ECM synthesis were partially or closely correlated (27, 28) , but the increase in kidney size was not attributed Moreover, the possibility that opioid-exposure may lead to enlarged kidneys and subsequent hyperfiltration-mediated injury, as is seen in diabetes and sickle cell disease, is of concern in opioid-based treatments of pain. Glomerulopathy is associated with the development of secondary focal and segmental glomerulosclerosis (25,32,44).
Morphine Stimulates Proliferation of Mesangial Cells in vitro via KOR
Increasing evidence suggests that genetic factors play a critical role in the development of glomerular disease (10,15). For example, C57/BL6 mice were shown to be glomerulosclerosis resistant vs ROP mice, which were prone to glomerulosclerosis (15, 23, 30) . The oligosyndactyly (Os) mutation and streptozotocin treatment in both ROP and C57/BL6 mice led to glomerular volume expansion and mesangial cellular proliferation, but only ROP mice developed sclerosis. Interestingly, in ROP mice glomerular volume continued to increase, whereas, it plateaued in C57/BL6 mice.
Similarly, we observed that even though MS treatment lead to an increase in glomerular volume, it did not result in any other pathological lesions or alteration in GFR or proteinuria in our study using the C57/BL6 strain. In contrast, in a recent study on tumor-bearing C3H mice, we observed that 3 weeks of MS treatment lead to an increase in glomerular volume, PCNA expression, tubular dilatation, peri-tubular congestion and tubular casts (4), and these MS-induced histopathological changes were accompanied by proteinuria, increased blood flow in the kidneys and decreased mean arterial pressure, even though these mice did not show any metastasis in the kidney or other changes due to the growth of subcutaneous tumor. Differences in the presentation of renal disease in MS treated C3H mice described by us earlier and in C57/BI6 mice in this study suggest that genetic factors are critical to the development of MS-induced nephropathy. Although no well controlled studies are available on drug users, the available studies show membranoproliferative glomerulonephritis in white users and focal segmental glomerulosclerosis in black heroin users (1, 14, 16, 29, 41, 42) .
The heterogeneity in response to heroin is speculated to be due to variability in socioeconomic background, viral infections and paucity of prospective controlled studies, in addition to differences in genetic susceptibility.
It is believed that mesangial proliferation occurs in response to increased cytokines secreted by the infiltrating macrophages in the mesangium. Since MS treatment did not
show an increase in macrophages, the increased population of mesangial cells in MS treated mouse kidneys appears to be due to a direct effect of MS on mesangial cell proliferation. Our data therefore argue for MS-induced mesangioproliferative glomerulopathy in this mouse model. 22 We therefore sought to identify the OR associated with MS activity in mesangial cells, using C57/BL6 mice deleted for ORs. Since C57/BL6 mice develop mesangial and glomerular volume expansion which precedes more severe glomerular disease in humans, it appeared to be a suitable strain to identify the OR associated with early glomerular disease initiated by MS.
We found in the present study that MOR and KOR were expressed in the kidney as well 
